GIUSEPPE NOVELLI

CURRICULUM VITAE

POSITION	Full Professor of Medical Genetics, University of Rome "Tor Vergata" NVLGPP59B27H579C
INSTITUTIONAL ADDRESS	Via Montpellier, 1 00133 Rome, Italy

EDUCATION AND TRAINING

1983 - 1985: Specialization in Medical Genetics, University of Rome "La Sapienza".
1981 - 1987: Teaching and research activity at the Faculty of Pharmacy of the University of Urbino "Carlo Bo".
1977 - 1981: Degree in Biological Sciences *summa cum laude*, University of Urbino "Carlo Bo".
2020 – 2021: Degree in Management Training for Healthcare Company Managers, Executive programme, LUISS Business School, Rome

INSTITUTIONAL ASSIGNMENTS AND MEMBERSHIP

2025 - present:	Member of the Scientific Committee of the Ultrastructural Biophysics Research Institute (UBRI)
2025 - present:	Member of the Scientific Committee of SKILLAB (Corporate Academy of Vittoria Assicurazioni Spa)
2025 – present:	Member of the Executive Board of Obesity Policy Engagement Network (OPEN)
2022 - present:	Member of the Board of Directors and of the Scientific Committee of the Balsano Foundation
2021 - present:	Member of the Scientific Committee of the Aldo Torsoli Foundation
2021 - present:	Member of the Scientific Committee of the Observatory for Rare Diseases
2020 - present:	Expert for the European Medicines Agency – Malta.
2019 – present:	Member of Boards of Directors, IBDO Foundation
2019 - present:	President of the Giovanni Lorenzini Foundation, Italy
2019 - present:	Member of the Scientific Committee of the Italian Sports Medical Federation (FMSI)
2016 - present:	Member of the National Committee for Biosafety, Biotechnology and Life Sciences – CNBBSV, and Coordinator of the Genetics Subgroup of the CNBBSV, Presidency of the Council of Ministers.
2012 - present:	Consultant for Genetics of the Research Center "IRCCS Neuromed", Pozzilli (IS).
2016 - 2019:	President of the National Observatory for Health Professions, MIUR.
2016 - 2019:	Expert for the European Medicines Agency – EMA, London.
2018 – 2019:	Delegate of the Conference of Italian Rectors – CRUI for issues related to university health.
2013 - 2018:	Member of the Superior Council of Health, Ministry of Health.
2016 - 2018:	President of the Medical Genetics Commission 06/A1 for the National Scientific Qualification, MIUR.
2009 - 2018:	President of the Board of Full Professors of Genetics Med/03
2016 - 2017:	Member of the Genome Project National Committee, Ministry of Health.
2014 - 2017:	Vice President of the Conference of Italian Rectors – CRUI.
2002 - 2016:	Member of the Ethics Committee of the Policlinico Tor Vergata – PTV.
2008 - 2015:	Member of the Pharmacogenomics Working Party (PgWP) at the European Medicines Agency - EMA, London.
2011 - 2013:	Member of the Board of Directors of the National Agency for the Evaluation of the University and Research System – ANVUR.
2010 - 2013:	Member of the European Science Foundation (ESF)
2008 - 2011:	Dean of the Faculty of Medicine and Surgery of the University of Rome "Tor Vergata".

1998 - 2000: Member of the Research Committee of the University of Rome "Tor Vergata".
1999 - 2000: Member of the Scientific Committee of the National Research Council – CNR.
2006 - 2007: Member of the Working Group on "Expert of Advanced Therapies", Italian Medicines Agency (AIFA).
2006: Member of the Rare Diseases Committee and Delegate for the Lazio Region, Ministry of Health.
2000: Member of the Study Commission on the Use of Stem Cells, Department of Planning of the Ministry of Health.
1998 - 2000: Member of the Research Committee, University of Rome "Tor Vergata".
1999 - 2000: Member of the Scientific Committee of the CNR ("Tor Vergata" area).
1998 - 1999: Member of the Working Group on Cloning, Presidency of the Council of Ministers.
1996 - 1998: Member of the Ethics Committee of the School of Medicine of the University of Rome "Tor Vergata".
1992 - 1995: Consultant of the Scientific Police, Ministry of the Interior.

OTHER ASSIGNMENTS

He is an external expert at *the Agencie d'évaluation de la recherche et de l'enseignement supérieur (AERES)*, in France; he was a member of the National Post-Genome Commission of the Ministry of University and Scientific and Technological Research (MURST); he was representative for Italy at the OECD (Organisation for Economic Co-Operation and Development) for genetic testing; he was a member of the "Groupe d'experts en Genetique moleculaire", at the Ministère de la Santé, de la Famille et des Personnes Handicapées, in France; he has been a reviewer for the National Research Agency (ANR), France, since 2009. He is a member of the "Board of Trustees" of the Biagio Agnes Foundation. He was *advisor* for the spin-off Onconetics (USA).

ACADEMIC AND RESEARCH EXPERIENCE

2024 – present: Member of the Scientific Advisory Board "Anemocyte", at Biotech Manufacturing Organization (Milan, Italy)
2019 - present: President of the Giovanni Lorenzini Foundation, Milan.
2019 - present: Expert Evaluator for the Maltese Medicine Authority.
2001 - present: Director of the U.O.C. Laboratory of Medical Genetics of the Policlinico di Tor Vergata.
1999 - present: Professor of Medical Genetics at the Faculty of Medicine and Surgery of the University of Rome "Tor Vergata".
2016 - present: Adjunct Professor of the University of Nevada, Reno School of Medicine, USA.
2003 – 2019: Adjunct Professor at the University of Arkansas for Medical Sciences, Little Rock, USA.
2013 - 2019: President of Fondazione Policlinico Tor Vergata Foundation
2011 - 2015: Scientific Director of the Fatebenefratelli Research Center of the San Pietro Hospital in Rome.
1998 - 2011: Director of the School of Specialization in Medical Genetics, University of Rome "Tor Vergata".
1996 - 1997: Visiting Professor "MiniSabbatical" at the University of Southern California (USC), Los Angeles, USA.
1995 - 1999: Associate Professor of Human Genetics at the University of Rome "Tor Vergata".
1992 - 1995: Associate Professor of Molecular Genetics at the Faculty of Medicine and Surgery of the Catholic University of Milan, Rome – Policlinico Gemelli.
1990: Associate of the Groupe de Génétique Moléculaire INSERM U.91, Créteil, France.
1983 - 1992: Researcher of Molecular Genetics at the University of Urbino "Carlo Bo".
1983 - 1984: Visiting Researcher at the Unité de Recherches de Biologie Prénatale INSERM U.73, France.

AWARDS

2025: " Ambassadors of Excellence Award, Liber Association", Rome
2025: "Springer Nature Author Service Award"

2025: "Springer Nature Editorial Contribution Award"
2025: "Magister Magnus" Award, Fondazione Scuola Medica Salernitana
2024: "Award for Wound Care Education" – Italian Academy Wound Care (IWAC)
2024: "Maxima Laude" Award, Associazione Liber, Rome
2024: Order of Minerva from the University of Studies "Gabriele d'Annunzio", Chieti
2024: URBES Award, Health City Institute for the important research activity in the field of studies on epigenetics as a fundamental component to understand the impact of urbanization on people's health
2023: "Celia Carrion Perez de Tudela" Award (International Association of Relatives and People Affected of Lipodystrophy, Spain) for the Scientific Contribution to Congenital Lipodystrophies and Progeroid Syndromes
2023: "Radici" Award, Award Ass Cariatesi (CS)
2018: SIMI Medal, Italian Society of Internal Medicine
2017: Order of Merit of the Italian Republic
2017: National Medicine Award, Pescara
2016: Rocco Docimo Award, Cosenza
2015: Gaetano Conte Award for Neuromuscular Disorders
2014: Premio Benemerenza Scilla Cuore
2015: Alvaro Prize for Science and Culture
2011: Scanno Prize for Medicine (XXXIX edition)
2011: Premio National Gentile di Fabriano per la Scienza e l'Innovazione, XV Edition
2009: International Prize Calabria in the World
2009: "Vittorio Aprile" Award, Rome
2004: Pericle D'Oro Award for Scientific Research
2003: "Brutium" Science Award
2002: "Ferrari" Award Italian Society of Human Genetics (SIGU)
1984: Italian Association of Handicap Research and Treatment Award

ACTIVITIES AND AREAS OF SCIENTIFIC RESEARCH

Mapping, identification and cloning of new genes in humans

He began his research activity in the field of Biochemistry and Genetics in 1980.
His main interest has been the mapping, identification and characterization of human diseases of genetic origin (Laron syndrome, Cystic fibrosis, DiGeorge syndrome, Mandibuloacral dysplasia, Friedrich's ataxia, Spinal muscular atrophy, myotonic dystrophy, psoriasis, galactosemia, hereditary hemolytic anemia, atherosclerosis and myocardial infarction, vacuolar neuromyopathy, Patella aplasia hypoplasia). *The Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study* (J. Med. Genet.: 34 Issue: 10 Pages: 798-804, 1997) provided scientific evidence that patients with deletion of the 22q11 region manifest a heterogeneous spectrum of symptoms and phenotypes. This fundamental study, cited more than 398 times, provided evidence for the first time of the phenotypic complexity associated with this syndrome and suggested the involvement of several genes located within the chromosomal region 22q11.
In the same year, Prof. Novelli focused his studies on the gene mapping of the region that allowed him to isolate and characterize a new gene, UFD1L, responsible for the ubiquitination process, expressed during development, located within the region deleta 22q11 (Hum Mol Genet., 6, 259-265, 1997). After isolation, Prof. Novelli studied the structure, expression, and evolutionarily conserved function of this gene, as well as its pathogenetic role. For these studies (a total of 24 peer-reviewed articles), Prof. Novelli wrote two editorials (*Trends Genet*. 1999 Jul;15(7):251-4 and *Mol. Med. Today*, 2000 Jan;6(1):10-1). The results obtained during this period have earned him participation in an EU consortium directed by P. Scambler and favored his collaboration with researchers and geneticists, in order to characterize the molecular mechanisms involved in the pathogenesis of the disease.
In collaboration with Dr. Meisterernst M. (Munich, Germany), Prof. Novelli subsequently published the cloning of a new gene, PCQAP (PC2 glutamine/Q-rich-associated protein), which maps within the deletion region and encodes a protein that constitutes a subunit of the large multiprotein complex PC2 (Genomics, 2001 Jun 15;74(3):320-32).
Continuing his research in this field, he focused his attention on the study of the regulatory effects of haploinsufficiency of the 22q11 region during development, analyzing the expression pattern of the MM16 orthologist gene in mouse embryos at different stages of development (Gene. 2007, 391(1-2):91-102) and studying its morphogenetic mechanisms in a mouse model of the disease. (Cardiovasc Pathol. 2006 Jul-

Aug;15(4):194-202). Further studies have shown that periconceptional administration of folic acid and methonin are able to influence the incidence of congenital defects and may probably induce negative selection of embryos presenting with developmental abnormalities (Cardiovasc Pathol. 2008 Apr 14).
In a 2002 publication (Am J. Hum Genet., Aug;71(2):426-31), Novelli demonstrated for the first time that the mutation of a single nucleotide in the LMNA gene is responsible for a Progeroid Syndrome, Mandibuloacral Dysplasia (MAD) and suggested that this protein is actively involved in premature aging. Mutations in the LMNA gene have been found so far to be causative to about 26 different diseases, called "Laminopathies", including Muscular Dystrophy, Cardiomyopathies, Muscular Dystrophy, Lipodystrophy, Insulin Resistance, Diabetes, and Premature Aging. The involvement in this field is documented so far in 11 peer-reviewed articles published in prestigious journals (i.e. Hum Mol Genet., Exp Cell Res., Aging Cell, J Clin Endocrinol Metab, Physiol Genomics) and led to the establishment of a European Network funded by EU FP6 funding "Euro-laminopathies" no. 018690 (http://www.projects.mfpl.ac.at/euro-laminopathies/php/index.php).
The identification and characterization of an endothelial lipoprotein oxidized lipoprotein receptor splicing isoform (ox-LDLs): LOXIN, encoded by the OLR1 gene, has demonstrated a protective role of LOXIN in diseases related to LOX-1 overexpression, such as arteriosclerosis and tumors (Rev.. In Int J. Mol. Sci.2017).

Gene therapy

In collaboration with D. Gruenert (San Francisco, USA), Prof. Novelli has developed an innovative gene-targeting technique based on oligonucleotides to restore proper gene function through homologous recombination using small DNA fragments (SFHR: Small Fragment Homologous Replacement). In a series of articles published in Hum Mol Genet., Mol Therapy, Biotechniques, Hum Gene Ther., J. Clin Invest) demonstrated the validity of these techniques to correct mutated human cells in *vitro* and *in vivo*. Recent developments and new strategies have led to evidence that SFHR could be used in clinical therapy protocols for genetic diseases, and cell gene therapy. This technique serves as the prototype for the current *gene-editing approach.* Within the National Center for the Development of Gene Therapy and Drugs with RNA Technology, of which he is the coordinator of WP2, spoke 5 https://www.rna-genetherapy.eu, Prof. Novelli's laboratory is developing a new and original technology for the degradation of viral genomes mediated by CRISPR-CAS using miRNAs differentially expressed in infected and uninfected cells (unpublished data).

Stem cells

Using immunohistological analysis and FACS, it was possible to isolate and characterize multipotent cells derived from human cytotrophoblasts (hCTMCs) from chorionic villus sampling (CVS). These cells represent a safe and convenient source of cell therapy as well as an ideal target in in utero fetal gene therapy protocols (Cloning Stem Cells, 2009).
Subsequently, an original protocol for treating Pulmonary Fibrosis in a mouse model was developed. This study has opened new perspectives for the use of AECII cells derived from HUES stem cells in the therapy of a still lethal and incurable lung disease (Eur Resp J. 2012)
A model of cancer stem cells was developed from human stem cells derived from amniotic and chorionic membranes. These cells can differentiate into neural cells and initiate a spontaneous transformation process by acquiring an *NB-like* phenotype (Stem Cell Res Ther. 2014).
Finally, a protocol has been developed that allows the reprogramming of induced pluripotent human stem cells (hiPSCs) from patients suffering from genetic diseases. HiPS cells represent an important tool for human health, as they represent a valid in vitro model for the study of monogenic diseases, allowing the study of their pathogenetic mechanism in gene and cell therapy protocols (Cell Reprogram 2015). Analysis of volatile compounds (VOCs) released *in vitro*. During the reprogramming of these cells and their differentiation, it was subsequently characterized (Sci Reports, 2017; Bioprotocols, 2017). In recent years, his group has developed technologies to develop human organoids from patients with rare diseases and study models for viral infections (J Mol Cell Cardiol, 2018; Front Physiol, 2018; Hum Genom, 2020; Cells, 2022; Front Cell Dev Biol, 2023; Cell Mol Bioeng, 2021).

Personalized Medicine, Pharmacogenetics and Pharmacogenomics

Personalized medicine allows doctors to know the molecular constitution of each patient. Knowledge of the patient's specific genetic profile helps the doctor select patients to whom to offer a specific therapy tailored to the individual's characteristics. Personalized medicine is a direct extension of genomic medicine that uses genetic information to prevent or treat disease in adults or their children. In this field, Prof. Novelli has developed an original protocol and identified new genomic biomarkers for the efficacy of drugs and their adverse effects

(Pharmacogenomics 2014, 2015, 2016, 2017). Recent studies have been directed to Stevens-Johnson syndrome, a toxic epidermal necrolysis associated with specific drugs It also highlighted how genetic variations in microRNA candidate genes (miRNA or miR) could contribute to susceptibility to complex diseases such as diabetes, lupus and Chron's disease (Acta Diabetol, 2016, Molec Diagn Ther, 2017, Plos One 2016, Pharmacogenomics 2017, Genes, 2021; Lupus, 2021; Epigenomics, 2021; Epigenomics, 2024). Recently, Prof. Novelli's group demonstrated for the first time the role of the lncRNA MEG3 in the response to treatment with ant-TNFa biological drugs, allowing the identification of responders to the drug (Int Immunopharmacol., 2024). Prof. Novelli is responsible for the Predictive and Precision Medicine Clinic at the Policlinico Tor Vergata in Rome. This clinic is aimed at people who wish to know their risk of developing hereditary-familial diseases, improving their quality of life, providing valuable information on their health status, and helping them make informed decisions on disease prevention and treatment. https://www.ptvonline.it/index.php/mnu-utenti/visite-esami/ambulatorio-medicina-personalizzata-e-di-precisione. Recently, a very large study demonstrated that the electrocardiogram (ECG) correlated accurately with the genotype proved to be of high prognostic value (JACC Adv, 2025).

Oncogenetics and Cancer

His contribution to cancer is documented by the identification and characterization of the human DVL 1 gene, a member of the Disheveled family involved in Wnt signaling that governs several cellular processes including cell proliferation, survival, migration, differentiation, polarity and stem cell renewal (Hum Mol Genet. 1996; Am J Hum Genet. 1996), by the definition of the role of the OLR1 (LOX-1) gene as an oncogene through the activation of NF-kB target genes responsible for proliferation, migration and inhibition of apoptosis (PLoS One. 2011; Stem Cell Res Ther. 2014.; Oncotarget. 2016; PLoS One. 2016; Int J Mol Sci. 2017; Int J Radiat Oncol Biol Phys. 2017; Cell Death Dis. 2019; Front Oncol. 2019; Cancer Gene Ther. 2021; Cancers, 2021), and de novo lipogenesis genes, to the identification of POLD1 (DNA polymerase δ) gene mutations in multisystem disorders of aging and cancer (Nat Genet. 2013; Ageing Res Rev. 2018; DNA Cell Biol. 2018; Aging, 2021, 2022; Mech Ageing Dev. 2023). Furthermore, Prof. Novelli has been involved in pharmacogenetics and pharmacogenomics by identifying new markers and developing innovative diagnostic technologies such as liquid biopsy, mutation analysis and applying the polygenic score (PRS) in the predictive risk assessment of cancer (Pharmacogenomics. 2004; Pharmacogenomics 2007; Neuroradiol J. 2015; Oncotarget. 2016; Sci Rep. 2018; Cell Death Dis. 2019; Front Oncol. 2019; Cell Death Dis. 2019; Semin Cancer Biol. 2021; Hum Genom, 2021; Hum Mol Genet. 2022; Oncogene. 2023; Heliyon, 2023; J. Pers. Med., 2024).
Prof. Novelli is a founding member of Tor Vergata Oncoscience Research (TOR) https://centrotor.uniRome2.it/ , a Center of Excellence of the University of Rome Tor Vergata launched in 2020 (G. Melino, M. Roselli, A. Mauriello, O. Bonomo). TOR aims to promote an international cancer research network through constructive interaction and discussion with departments, international publishers, research centers, universities, research hospitals, scientific societies, potential industrial partners and active international collaboration networks. TOR has created worldwide networks with several local and international research partners. Three international agreements are already in place. A representative partnership is the agreement established with Indivumed GmbH (https://www.indivumed.com), to form an international scientific consortium with the aim of building a biobank and large datasets of comprehensive genomic, proteomic and lipidomic data with complete clinical data of cancer patients. This big data will be integrated into an international alliance, Onco AI-Med, to produce an advanced precision oncology approach based on artificial intelligence. Indivumed GmbH founded in 2002, CEO Hartmut Juhl, is a global integrated oncology company based in Hamburg, Germany, using a multi-omics approach for rapid high-quality analysis of cancer compared to normal tissue. The company was a member of the TCGA consortium. In January 2020, an agreement was signed for the analysis of 200 patients/year for whole genomic sequencing, proteomic and lipidomic analyses correlated with complete clinical data for at least 5 years thereafter. The project will focus on liver, kidney, bladder, colorectal cancers. The data will be exchanged and analyzed with the 16 partners of Indivumed in North/South America, Europe and Asia. The cumulative results would facilitate the optimization of individualized therapy. Onconetics Pharmaceuticals Inc. (www.onconetics.com), San Francisco California USA, founded in 2016 by Gabe Hitchcock and Luke Gruenert, is engaged in the research and development of drugs for the emerging and highly sought-after field of personalized medicine to develop treatments for cancer and other genetic diseases. It combines an established gene therapy that exploits micro-RNA.
Prof. Novelli is a member of the Project "MOLECULAR TUMOR BOARD IN THE ONCOLOGICAL PATIENT" presented to the Lazio Region by the General Management of the Policlinico di Tor Vergata for authorization and activation (2024).
Prof. Novelli's laboratory at the Policlinico di Tor Vergata has been chosen for the validation of the "Prostatype"

test for the evaluation of the aggressiveness of prostate cancer, to help physicians and patients make correct decisions about treatment for individuals with prostate cancer. This innovative test, developed by the Swedish company Prostatype genomics (https://www.prostatypegenomics.com/), allows for the minimization of over- and under-treatment, improving patients' quality of life and reducing healthcare costs. Prostatype uses prostate tissue from a biopsy obtained at the time of diagnosis (i.e. no new sampling of the prostate is necessary).

Forensic DNA Analysis

Prof. Novelli introduced forensic DNA analysis for the first time in Italy (Nature 1991). Together with his group he has developed many protocols and platforms for DNA analysis at the crime scene (Forensic Sci Int Genet. 2007; BMC Genomics. 2007; Curr Genomics. 2008; J. Forens. Sci, 2009; Forensic Sci Int Genet. 2010; Nanomedicine (Lond) 2011).

COVID and Immunogenetics

In recent years, Prof. Novelli has been working on host genetics in Covid-19, identifying for the first time potentially lethal rare mutations in the genes encoding interferons (Zhang et al, Science, 2020). In this context, it has identified the first monoclonal antibodies against SARS-CoV-2, and discovered one of the first antiviral molecules against COVID-19, indole-3-carbinol, for which production and clinical trial projects are also being developed (Genes, 2020; HLA. 2020; Clin Exp Rheumatol. 2020; Hum. Genom, 2020; Heliyon, 2020; Indian J Med Res. 2021; Cell Death Dis., 2021; Cell Death Dis. 2021; J Clin Invest. 2021; J Mol Biol. 2021; Genes, 2022; Nat Immunol. 2022; Cells, 2022; Hum Genom, 2022; Cell Death Discov., 2022; Nature Immunol, 2022; Cell Rep., 2022; J Cell Mol Med. 2022; ACS Chem Biol. 2022; Hum Genom, 2023; Front Microbiol. 2023; Viruses, 2023; Pharmaceuticals, 2024).
Within the International Consortium, COVID Human Genetic Effort, of which he is a founding member, he participated in several collaborative studies whose results have been published in: Science, 2020, Science Immunol, 2021; J. Invest Dermatol, 2021; Nature, 2022; Nature Med., 2022; Science, 2023; J.exp. Med., 2022; Nature Immunol, 2022; Genome Med., 2023; HGG Adv., 2024; J. Allergy Clin Immunol., 2023; J. Clin Immunol. 2023). All these studies have allowed us to define the SARS-CoV-2 infection and its relationships with the host at the molecular level. A recent study allowed Professor Novelli's group to demonstrate the biological effects of a heterozygous nonsense mutation in the TLR3 gene (p.Trp769*) in a lung organoid (hLORG) model. The study demonstrated that, after SARS-CoV-2 infection, the mutation induces significant upregulation of fibrinogen genes (FGA, FGG) (Cell Death Discover, 2025).

Contribution to the dissemination of science

Giuseppe Novelli has been actively involved in scientific dissemination in Italy at various levels, in the field of human genetics, medical and molecular, and has held public conferences on different topics. He has regularly given interviews and contributes to the most authoritative organs of the Italian press, such as newspapers, paper magazines, online scientific or speaking on radio and television programs.

MAIN RESEARCH PROJECTS

– 2002-2004: "Genetics and Genomics of Atherosclerosis" MIUR.
– 2002-2004: "Dissecting mendelian phenotypes" MIUR (FIRB Funds).
– 2002-2004: "Operative network on Neuromuscular Disorders", Ministry of Health.
– 2002-2004: "Neurogenetics of neurodegenerative disorders" Ministry of Health.
– 2002-2004: "Research of cystic fibrosis phenotype modifier genes" MIUR.
– 2003- 2005: "MAD and laminophaties" Telethon Italia.
– 2005-2007: Pathophysiology and therapeutical approaches in MADA, a rare progeroid syndrome. Rare Disease Project: Conv. n. 526/A13. Istituto Superiore della Sanità.
– 2005-2009: EU funding FP6 NACBO "Novel and improved nanomaterials, chemistries and apparatus for nanobiotechnology".
– 2005-2007: AIRC (Italian Association for Cancer Research) "Genomics of Human Prostate Cancer". – 2005-2007: Congentital heart defects: genetics, embryology and clinical apsects. MIUR.
– 2004-2007: Genetics of Cystic Fibrosis. Lazio Region.
– 2005-2008: EU funding FP6-2004-LIFESCIHEALTH-5: Nuclear Envelope-linked Rare Human Diseases: From Molecular Pathophysiology towards Clinical
– 2006-2008: Biomarkers identification in heart failure. Ministry of Health.

– 2005-2007: Myotonic dystrophy type 1 and type: from pathogenesis to development of innovative gene therapies (PRIN # 2005064759). MIUR.
– 2006-2007: Development of screening programs for beta-thalassemia prevention in Albania. Ministry of Foreign Affairs.
– 2007-2008: Development of screening programs for cystic fibrosis prevention in Albania. Ministry of Foreign Affairs.
– 2006-2008: Causes, evolution and progression of nasal polyps; role of modifier genes and a new approach through CGH array. Cystic Fibrosis Foundation, Italy.
– 2007-2009: Development of an RNA interference-based system for the molecular cell therapy of myotonic dystrophy. Telethon financing.
– 2007-2009: Identification of biomarkers during steorid doping. Ministry of Health.
– 2007-2009: Study of efficacy of statins in association with biphosphonate in Mandibuoloacral dysplasia and Hutchinson-Gilford Progeria. Italian Medicines Agency (AIFA). Approved.
– 2008-2010: New Gene therapy approach for DM1 and DM2. Association Francese contre le Myopathies, FM (France). Approved.
– 2009-2012 EU-FP7, BIO-NMD, Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders.
– 2010-2012: "Lipid metabolism and cancer: LOX-1 a new potential molecular target in colon cancer therapy". Umberto Veronesi Foundation.
– 2021: "Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells". Fondazione Rome.
– 2021: "GeCoBioMark", POR-FESR Gruppi di Ricerca 2020.
– 2021: "STEMCOmAb", FISR2020.
- 2022: "Piano Sviluppo e Coesione Salute" (FSC 2014-2020. T3-AN-04 GENERA).
- 2022: "European Union – NextGenerationEU, PNRR M4-C2-1.4 (CN00000041); "UNDINE", HORIZON-HLTH-2021-DISEASE-04-07.
- 2022: "Italian Ministry of Research MUR program PNRRM4-C2-I1.1 PRIN2022 "HECORES" (2022ZSLRPT)
- 2022 - 2025: MUR CN_00000041 - CN3 - National Center for Gene Therapy and Drugs based on RNA Technology, PNRR
- 2022 - 2025: MUR PE00000019, PNRR "HEAL Italia", Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine
- 2022 - 2025: MUR PE00000006, PNRR M4-C2-I1.3 MNESYS – A multiscale integrated approach to the study of the nervous system in health and disease,
- 2023 - 2025: M6-C2-I2.1PNRR-MR1-2022-1237587, Development of an integrated tool based on genetic, epigenetic and clinical analysis to optimize the diagnosis, prognosis and treatment of myotonic dystrophies (GEPINDM)

PERSONAL SKILLS

Organizational/managerial skills

Giuseppe Novelli has previously held prestigious scientific and administrative positions such as Dean of the Faculty of Medicine (2008-2010) and Rector of UNITOV (2013-2019). The University of Rome Tor Vergata (UNITOV) is a young, medium-sized, research-oriented university in the south-east of Rome, located on a 600-hectare campus. UNITOV comprises 6 faculties: Economics, Engineering, Humanities and Philosophy, Law, Mathematical, Physical and Natural Sciences and Medicine and Surgery, including a complex integrated hospital system for care, training and research: the Policlinico Tor Vergata. UTOV is strongly rooted in the local community and the campus hosts several national research centers such as: CNR (National Research Council) and ASI (Italian Space Agency). UNITOV is deeply committed to excellent scientific education and research and collaborates closely with the private sector, public institutions and non-profit organizations at national and international level. It promotes technological, organizational and social innovation necessary to achieve sustainable development in Italy and worldwide, following the Sustainable Development Goals approved by the United Nations in September 2015. UNITOV participates in several international networks to improve the interdisciplinarity of curricula, research activities and mobility of the academic community, and is fully committed to promoting a global dimension of studies. UNITOV has a solid experience in the management and supervision of research projects. UNITOV has managed over 245 projects funded by EU programs (FP7, H2020) and other public and private funding organizations. UNITOV is also involved in several international networks such as EUA, UNICA, YERUN VIU. 5 JU (FCH Fitup, LOLIPEM, ECSEL, M2O, Harmony) and in 1 KIC (HEInnovate). Researchers from the Departments of Experimental Medicine, Biology, Systems Medicine, Biomedicine and Prevention,

Chemical Science and Technology and Business Engineering have been involved in several collaborative projects, including HORIZON 2020 Eurobench, to develop a benchmarking solution for specific scenarios, including one or more testbed results, software routines and/or experimental datasets. HORIZON 2020 COGIMON, which addresses the interaction problem requiring active and adaptive regulation of both human and robot movement and behavior and involving whole-body variable impedance actuation, adaptability, prediction and flexibility. AMARSI FP7-ICT which aims at a qualitative leap towards the biological richness of robotic motor capabilities. MINDWALKER FP7-ICT which combines physiological, clinical and robotic expertise to develop an integrated brain-machine system that undergoes a clinical evaluation process with patients with spinal cord injury. FP7- FLORINASH addressing the effects of the gut microbiome on metabolic disorders during aging (see Nat Med. 2018 Jul;24(7):1070-1080); FP7-EURHYTHDIA investigating lifestyle chronotherapeutic intervention for diabetes and obesity to restore circadian rhythm and improve cardiometabolic risk in the European working population. IMI2 SOPHIA is investigating novel approaches to stratifying obesity phenotypes to optimize future obesity therapy. VIGOUR, to support health authorities in transforming their health and care systems and to provide sustainable models for integrated care.
Prof. Novelli has been a member of the Board of Directors of ANVUR (Italian National Agency for the Evaluation of Universities and Research) and Scientific Director of the Fatebenefratelli Research Center, San Pietro Hospital, Rome, Italy. Prof. Novelli contributed to creating the Young European Universities in the EU (Yerun, https://www.yerun.eu/). YERUN is a non-profit association that brings together young research-oriented universities in Europe. YERUN represents 18 universities from 12 EU countries. He was the creator of the European YUFE network. YUFE is a new model of an open and inclusive European University. This facilitates interactions and increases dissemination through the network.
Prof. Novelli has extensive experience managing and coordinating working groups, including international ones, dedicated to scientific, diagnostic and third mission activities. He is responsible for the Biobank for the conservation of biological samples (subject to appropriate Informed Consent) operating at the Policlinico Universitario Tor Vergata (GEFACOVID) according to the BBMRI-ERIC Biobanking and Biomolecular Resources Research Infrastructure criteria, www.bbmri.eu) Within a project funded by the EU (UNDINE).

As Director of the UOC of the Laboratory of Medical Genetics, Prof. Novelli has the coordination of 30 people, including nursing staff, department staff, doctors, biologists, technicians and administrators, extensive expertise in budget management, defining operational guidelines, and designing diagnostic programs.
In co-coordination with Dr. Bengala Mario, he is responsible for the Reference Center for Rare Metabolism Diseases (code: 12092001) of the Policlinico Tor Vergata, recognized by the Lazio Region (https://www.ptvonline.it/index.php/mnu-azienda/column-1-azienda/2013-05-23-11-18-21/malattie-rare-info-utenti). In 2024 (October), the healthcare production activity of the operating unit amounted to 3,394,023 euros, with an annual increase of + 28% in services and + 26% in revenues.

The medical outpatient, laboratory diagnostic and research activities of the UOC have been focused on the following areas of production and development: cardiogenetics, neurodevelopmental pathologies, constitutional oncology, prenatal diagnosis, cytogenomics, rare diseases.

Prof. Novelli collaborated in the definition of N.9 PDTA (Diagnostic Therapeutic Assistance Pathway) of the Policlinico Tor Vergata for the following pathologies: Marfan and related pathologies, Hereditary Angioedema, Melanoma, Breast Unit, Primary Immunodeficiencies, Neurodevelopmental Disorders, ALS, Juvenile Stroke, Congenital Immunodeficiencies.

MEMBERSHIP OF SCIENTIFIC SOCIETIES

2022: International Gender Medicine Society
2019: Academia Europaea
2010: Oligonucleotide Therapeutics Society (OTS)
2008: Medical Academy of Rome
2007: African Society of Human Genetics (AfSHG)
2005: Board Committee, American Society of Gene Therapy (ASGT)
2002 American Society of Gene & Cell Therapy (ASGCT)
1997: Founder Member, Italian Society of Human Genetics (SIGU)
1990: Human Genome Organization (HUGO)
1989: European Society of Human Genetics, Board (ESHG)

1988: American Society of Human Genetics (ASHG)

PARTICIPATION IN EDITORIAL BOARDS

2025- present: International Journal of Neuromuscular Diseases (IJND) Editorial Board
2024 - present: "GenoMed Connect". Regional Editor for the "Western Europe"
2024 – present: Journal of Translational Genetics and Genomics (JTGG) Editorial Board
2021 - present: *COVID* MDPI (Editor in Chief)
2020 - 2021: Genes (Guest Editor "Covid-19 and Molecular Genetics")
2019 - present IJMS - International Journal of Molecular Sciences (Editorial Board Member)
2019 - present Diabetes Monitor Journal (Co-Editor)
2019 - present Human Genomics (Associate Editor)
2009 - present: Plos One (Associate Editor)
2001 - present: Acta Myologica (Associate Editor)
2005 – present: Frontiers in Pharmacology
2005 – present: Frontiers in Genetics
2004 - 2019: BMC Medical Genetics
2004 - present: Encyclopedia of Life Science for Genetics and Molecular Biology
2000 - present: The Therapeutic Clinic
2002 - present: Journal of Cardiovascular Medicine
2004 - 2019: Journal Inflammation & Allergy – Drug Targets (IADT)
2010 - 2019: Genetics Research International
2005 - 2008: Journal of Pharmacogenomics & Pharmacoproteomics
1999 - 2013: Clinical Genetics, 1999-2013
1999 - 2003: Neuromuscular Disorders

REVIEWER FOR SCIENTIFIC JOURNALS

Acta Myologica, Advances in Pharmacological Sciences, Adv. Med. Sci., Am J Hum Genet, Am J Med Genet., Ann. Hum. Genet., Arch. Biochem.Biophys., Asian J Andrology, Arch. Dermatol., Ann Hum Biol, Expert Review of Anticancer Therapy; Atherosclerosis, Biology Direct, BMJ Case rep., BMC Medical Genetics; BBA Gene Structure & Expression, BBA - Molecular Basis of Diseases, BioTechniques, Cancer Biomarkers, Cancers, Cellular Signalling, Clin Genet, Clin. Chem. Lab.Med, Clin., Transl. Med., Comp. Struct. Biotec. J., COVID, Epigenomics, Eur J Neurol, *European Journal of Endocrinology,* European J. Clin., Future Sciences, Curr. Op. Cardiol., Exp. Med., Brain, eBiomed., Eur J Hum Genet, Eur. J. Med. Genet., Eur. Heart Journal, Functional & Integrative Genomics, Future Sciences, Neuromusc Dis, Immunogenetics, Indian J.Med. Res., Int. J. Mol. Sci , Int J. Exp. Pathol , J Endocrinol Invest; Chemistry/Today; Biol Neonat, Genetica, Gene, Genome Medicine, J. Dermatol. Invest., Circulation, Circulation Res, Cell Death and Differentiation, Development, Hum. Genet., Hum Reproduction, Mech. Ageing Develop., Mil. Med. Res., Molecular Medicine Today, Mol Genet Metab, Nature Genetics, Neuromuscular Disorders, Gene, Gene Express, Gene Therapy, Hum. Mol. Genet., Hum Mutat., Pharmacogenomics, Trends in Genet, Trends in Molecular Medicine, Biological Psychiatry, Thrombosis and Haemostasis, J. Biochem. Mol. Tox., J. Cardiov. Pharmacol., J. Cardiov. Med., J. Clin. Invest., J. Endocrinol Invest., J. Med. Genet., J. Mol. Medicine, J. Gene Medicine, J. Cardiovasc Pharmacol, Lancet, Gene Therapy, Mole Genet Metab, Mol. Hum. Repr., J. Mol Endocrinol, J. Clin. Endocrinol.Metab., Mol. Cytogenet. Mol. Therapy, PLOS One, PLOS Genetics, Lancet Neurology, Lancet, Nucleus, New England J. Medicine, Non-coding RNA Research, Resp. Res., Scient. Rep., Vaccine, Seminar Ophtalmol.

PUBLISHED BOOKS

Dallapiccola B., Novelli G.: Essential Medical Genetics, Ed. Phoenix Phoenix, 1998
Novelli G., Giardina E., Genetica Medica Pratica, Arcane, 2003
Dallapiccola B., Novelli G.: Genetica Medica Essenziale, Ed. Il Minotauro, Collana Phoenix, 2006
Dallapiccola B., Novelli G.: Genetica Medica Essenziale, Ed. CIC Internazionali, 2nd, 2012
Dallapiccola B., Novelli G.: Genetica Medica, Edizioni Scientifiche Falco, 2022
Dallapiccola B., Novelli G.: Genetica Medica Essenziale, Edizioni Scientifiche Falco, 2024
Dallapiccola B., Novelli G.: Fundamentals of Medical Genetics, Edizioni Scientifiche Falco, 2025
Novelli G., Orzes E.: Leggere i geni. Egea, 2025

IMPACT

Giuseppe Novelli has obtained four international patents.
– 2000: No. MI2000A 002041: "Method for the determination of the SMN1 Gene" filed on 19/09/2000. Italian. Y: no; LC: No.
– 2004: No. MI2004A000251: "Production of a monoclonal antibody for UBE4A protein and its use in diagnosis". Italian. Y: yes; LC: 1 (Abcam ltd.).
– 2005: WO /2005/080430 - Anti-ube4a/ufd2b polyclonal antibody and its use thereof as diagnostic and prognostic marker of 11q23 region alterations. International Application No.: PCT/IB2005/000305. Publication Date: 04.03.2006. International Filing Date: 02.08.2005. IPC: C07K16/40, G01N33/68, C07K16/00.
– 2006: WO/2006/137101 - Alternative splicing isoform of LOX-I protein encoding gene and uses thereof. International Application No.: PCT/IT2006/000470. Publication Date: 28.12.2006. International Filing Date: 20.06.2006. IPC: C12Q 1/68 (2006.01). Y: yes; LC: 1.
He established a Center of Excellence for the study of genomics, complex and multifactorial diseases at the University of Rome "Tor Vergata", funded by the MIUR in 2001.
He established Bioscience Genomics, a spin-off of the University "Tor Vergata".
He collaborated in the establishment of the Tor Vergata Oncogenomic Center (TOR);
He activated the Predictive and Precision Medicine Service at the Policlinico di Tor Vergata.
He was Chair and Organizer of the World Congress of Human Genetics, "Genomics in Precision Health", HUGO 2024, Rome.

BIBLIOMETRICS

ORCID: 0000-0002-7781-602X
Total number of publications in peer-review journals: 727
Total number of citations: 28.832 (Scopus)
H index: 73 (Scopus) – 68 (WOS)
D-index: 85
Citations: 32,902
World Ranking in Genetics: 1191
National Ranking in Genetics: 16
Novelli is named in the world's top 2% of Scientists List. (https://ecebm.com/2025/09/20/stanford-university-names-worlds-top-2-scientists-2025/).

National and International Lectures					
Title	**Event**	**Location**	**Type**	**Context**	**Year**
INTELLIGENZA ARTIFICIALE ED I PROGRESSI IN GENETICA	Il Medico di Medicina generale, l'ospedale e il territorio: Quali prospettive per una migliore integrazione	Salerno	Lettura	National	
AORTA, ANEURYSMS, AND DISSECTIONS: THE ROLE OF GENETICS IN SURGICAL STRATEGY	PTV Cardiac Surgery Focus – Capitulum II – "From Practice to Theory"	Rome, Tor Vergata University	Key Lecture	International	2026
Epigenetics: Bridging the Gap between Nature, Nurture and the Origins of Complex Illness	IMDP Medicine and Surgery Track	San Raffaele University, Milan	Seminar	International	2026
Cardiomiopatie: Genetica Molecolare	Master Medicina dello Sport	Università Foro Italico - Rome	Lesson	National	2026

Leggere i geni oggi. Perché leggere il DNA è come leggere un romanzo	Advanced Pre-clinical Models	Napoli- School of Pharmacy Federico II University	Seminar	National	2026
The Master Tailor: Why Precision Medicine Needs the Human Hand to Measure What AI Cannot See	Translation and Precision Medicine at the time of A.I. Advanced Technology and Digital Revolution	Rome	Interactive hybrid webinar	International	2026
Transforming lives through diagnosis: The key role of the geneticist in rare disease cure	SCIENTIFIC CONFERENCE OF RARE GENETIC DISEASE IV	Tirana	Conference	International	2026
Genetics and Genomics of Multiple Sclerosis: State of the Art and New Directions	2025 Masterclass on pregnancy in MS and antibody mediated neurological diseases	Rome	Masterclass	International	2025
Statuto biologico dell'embrione umano	Master II livello in Bioetica, Università Cattolica del Sacro Cuore	Roma	Lezione	Nazionale	2025
UPF ed Epigenetica: Il collegamento con l'invecchiamento biologico e le malattie croniche	Alimenti Ultraprocessati e Salute	Roma	Expert Meeting	Nazionale	2025
Genetic testing, screening and personalized medicine	XIV Congresso SISMED	Catania	Congresso	Nazionale	2025
Lo sviluppo del concepito	Lo Statuto Ontoogico del Concepito	Roma, Ponficia Università Antonianum	Convegno	Nazionale	2025
DAL FENOTIPO AL GENOTIPO NELLE MALATTIE CV: Principi di Genetica	86° Congresso Nazionale Società Italiana Cardiologia (SIC)	Roma	Congresso	Nazionale	2025
Il ruolo del test genetico delle aritmie. Aritimie cardiache	86° Congresso Nazionale Società Italiana Cardiologia (SIC)	Roma	Congresso	Nazionale	2025
Cardiogenetica predittiva: l'importanza dello studio del genoma per una diagnosi e una terapia di precisione	XIV Convegno Società Insubrica Cardiologica (SINCA)	Varese	Convegno	Nazionale	2025
Genetics, Precision Medicine & Biobanking: The Shields and Compass in the AI Tsunami	Cutting edge advancements in our fight against cancer	L'Aquila	Conference	Internazionale	2025
Environmental Exposures and Epigenetics: Protecting Children's Health	2nd International Conference of Environmental Medicine Environmental and Epigenetics: protecting children's health	Chieti, Università D'Annunzio	Conference	Internazionale	2025
AI e big data nella scoperta e sviluppo di biomarcatori	Biomarker discovery: dalla diagnostica alla	Roma	Convegno	Nazionale	2025

	target therapy				
Cardiogenetica oggi: tra biologia e clinica	Cardiobat 2025	Trani	Congresso	Nazionale	2025
Why genetic testing is important for most colorectal cancer patients	VII Colorectal Surgery Update & Campus	Rome	Convegno	Internazionale	2025
Epigenetica Sesso-specifica	Ambiente e differenze di genere: quale ruolo sullo stato di salute	OMCeO, Rimini	Convegno	Nazionale	2025
"Vita mia: l'inizio del grande viaggio". Lo sguardo aperto al mondo della scienza: la genetica, le biotecnologie, la sperimentazione sugli embrioni; le correzioni genetiche alla linea germinale.	Bioetica e Biodiritto. Il diritto di fronte ai temi etici: all'inizio della vita	Scuola Superiore della Magistratura, Scandicci	Corso	Nazionale	2025
Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine	International Collaboration UBRI Event	Mandaya Royal Hospital, Puri, Indonesia	Lecture	Internazionale	2025
Genomic Insights into Rare and Complex Diseases: From Gene Discovery to Precision Therapeutics	Disruptive Innovation in Precision Medicine: from molecule to bedside	Universitas Indonesia, Jakarta	Lecture	Internazionale	2025
Genetica e medicina personalizzata dalla prevenzione alla terapia	FNOB e all'Ordine dei Biologi	Reggio Calabria	Convegno	Nazionale	2025
La complessa interazione tra genetica e stile di vita nell'invecchiamento attivo	CardioBrixia	Brescia	Convegno	Nazionale	2025
Healthy by Choice or Sick by Chance: The Role of Predictive Genomic"	Università degli Studi LINK	Rome	Conference	National	2025
L'obesità: il risultato dell'interazione tra fattori ambientali e genetici	ITALIAN BAROMETER OBESITY FORUM 2025	Rome	Forum	National	2025
Lipodistrofie associate ad invecchiamento precoce. Il punto di vista del genetista medico	Lipodistrofie: un viaggio tra genetica, clinica e terapia.	Rome	Conference	National	2025
Farmacogenomica in cardiologia	Grandangolo in Genetica Medica 2025	Rome	Conference	National	2025
Contributo delle scienze OMICHE nella medicina cardiovascolare	The Annual Symposium of the Regional Reference Centre for Marfan Syndrome and Related Disorders	Rome	Simposia	National	2025
Invecchiare in Salute: Geni, Genomi ed Epigenetica	Conference Regionale SIBIOC	Cosenza	Conference	National	2025
Epigenetics in Chronic Diseases	IMDP, Medicine and Surgery Track. Lifestyle Medicine, UniSR	Milan	Seminar	International	2025

Cancro ereditario della mammella e dell'ovaio (HBOC): BRCA e oltre	Aggiornamenti Romeni di Medicina di Laboratorio, 4* Edizione	Rome	Conference	National	2025
Terapie Innovative basate sui geni: è possibile sognare il futuro?	WORKSHOP SALERNITANO. Il Medico di Medicina Generale, l'Ospedale ed il Territorio	Salerno	Conference	National	2025
Sani per scelta o malati per caso: a che punto è la ricerca?	L'innovazione nell'insegnamento delle Scienze nei curricoli della secondaria di I grado, aspetti contenutistici e metodologici, UnivRome3	Rome	Conference	National	2025
Modelling Severe Covid-19 in TLR3-mutated hiPSC-derived lung organoids	Human Genome Meeting (HUGO 2025)	Durban	Talk	International	2025
I tumor board e l'importanza della genetica in chirurgia colorectal	Master "Chirurgia Colorettale Laparoscopica e robotica", Univ Tor Vergata Roma	Rome	Seminar	National	2025
Is reading DNA enough to make a clinical diagnosis?	Towards clinical implementation of new generation genetic tests (NGS) in diagnosis of rare genetic diseases	Tirana	Conference	International	2025
Rosalind Franklin e l'eredità perduta	Rosalind Franklin Evento	Rome	Conference	Nazioanale	2025
I test di genetica medica oggi e applicazioni future	Innovazioni nei Test Genetici e Applicazioni Cliniche	Milan	Conference	National	2025
Influenza dell'ambiente sulla genetica: l'epigenetica	EMPOWERMENT. COME POTENZIARE LA PROFESSIONE-DNA E AMBIENTE	Rende	Conference	National	2025
Monoclonali come nuove armi terapeutiche contro i virus emergenti	Enterovirus, arbovirus e altri virus emergenti: un approccio one-health dalla prevenzione alla cura	Ferrara	Congress	National	2025
Lo statuto dell'embrione	Master Bioteica Univ Cattolica	Rome	Seminar	National	2025
Genomica Oggi: LA TIRANNIA DEI GENI?	Scuola di Genetica e Genomica FIB-FNOB-CNBG	Rome	Seminar	National	2024
Terapie geniche innovative	XIII Congress National SISMED	Venice	Congress	National	2024
Sani per scelta o malati per caso: si può modificare la tirannia dei geni? A che punto è la ricerca	XIII Congress SINCA	Varese	Congress	National	2024

Cardiomiopatie e selezione del paziente per ICD in prevenzioneprimari	Congress IACA – MAM	Desenzano del Garda	Congress	National	2024
Medicina predittiva abilitata dal genoma e interazione geni-ambiente	Giornata di Studio Nutrizione Clinica e Oncoloiga integrata: tra genetica, metabolismo e ambiente	Caserta	Course	National	2024
La genetica delle ferite	IAWC Meeting	Asti	Conference	National	2024
Genomica e suscettibilità individuale alle malattie dell'uomo	L' Arte Del Cuore"	Jesi	Conference	National	2024
La genomica predittiva	RomeCuore	Rome	Conference	National	2024
Test genomici: Innovazione e sostenibilità	Congress National SIFO	Napoli	Congress	National	2024
Ruolo dei cromosomi nelle malattie: differenze di genere	5 Congress National Medicina di Genere	Padova	Congress	National	2024
Cardiogenetica; tra prevenzione e terapia	CardioBrixia 2024	Brescia	Conference	National	2024
Medicina di precisione e farmacogenomica	Training Course on Germline and Somatic Pharmacogenetics (SIGU)	Cagliari	Course	National	2024
Gene Therapy	International Prix Galien Forum 2024	Rome	Forum	International	2024
Genomics in Precision and Personalized Medicine: How the management of complex and multifactorial diseases changes	Heal Italia Meeting	Palermo	Meeting	National	2024
Geni della salute ed esercizio fisico: un binomio per una sana longevità	II Congress National Cardiologia e Sport	Rende	Congress	National	2024
Genomica e suscettibilità individuale alle malattie dell'uomo	ScillaCuore	Scilla	Conference	National	2024
La genetica dell'obesità: l'obesità può essere congenita?	45° Congress National della Società Italiana di Medicina Estetica (SIME)	Rome	Congress	National	2024
Gjenetika dhe Gjenomika e Genodermatozave	Congress Regionale di Dermatologia	Tirana	Conference	International	2024
Genetica del Cancro e Riproduzione	III Giornate Napoletane di Medicina della Riproduzione	Napoli	Conference	National	2024
Sani per scelta o malati per caso: la tirannia dei geni	IX Workshop Salernitano	Salerno	Conference	National	2024
Ruolo della genetica ed epigeneticanel GDM	Diabete in Gravidanza	Rome	Course	National	2024
Mutazioni rare e alleli comuni: effetti sulla valutazione del rischio genomico in malattie	Scuola di Specializzazione in Genetica Medica	Univ. Trieste	Seminar	National	2024

complesse e multifattoriali.					
Geni della salute ed esercizio fisico: un binomio per una sana longevità	Federazione Medico-Sportivo, Sez. Sarda	Cagliari	Webinar	National	2024
Genomica e suscettibilitàindividuale alle patologie infettive e non	La Genomica in Patologia Clinica	Mestre	Conference	National	2024
Genomica: le istruzioni per una nuova strategia di lotta alle malattie (lo stargate per il futuro)	Meeting lariano delle scienze mediche	ASL Lecco	Conference	National	2023
Genomica: le istruzioni per uno stargate della medicina	Genetica medica: nuovi scenari dalla ricerca alla diagnosi	Barletta	Conference	National	2023
Nuovi farmaci legati alle terapie geniche	Festival della scienza medica	Bologna	Lecture	National	2023
Geni, cromosomi e genomi nella pratica clinica	"Cardio-brixia"	Brescia	Conference	National	2023
Ruolo della genetica nell'insorgenza del GDM	Diabete in gravidanza	Chieti	Conference	National	2023
Criteri di eleggibilità al test genetico per l'identificazione di varianti patogenetiche germinali nei geniBrca1 e Brca2	Asl5 Course di formazione	Guidonia	Course	National	2023
Varianti Rare e Alleli Comuni: Il caso del Cigno Nero	Università di Milan	Milan	National	intervento	2023
Genomics innovation: transforming healthcare, business, and the precision health	Xii Congress National SISMED	Napoli	Congress	National	2023
Malattie Rare e Ricerca	Malattie rare e PHTS: tra ricerca e percorsi di cura per una governance efficace	Palermo	Conference	International	2023
Training on strategies to foster solutions of undiagnosed Rare Disease cases		Rome	School	International	2023
Genetica del Breast cancer	Università Rome Tor Vergata – master radiologia	Rome	School	National	2023
Citogenetica e Citogenomica nella pratica clinica e nella medicina fetale	Università Rome Tor Vergata – master citogenomica	Rome	School	National	2023
Tecnologie al servizio dell'uomo: occorre un incubatore industriale	Ricerca e territorio	Rome	Conference	National	2023
FIRST TRIMESTER FETAL CHROMOSOMAL ANOMALY SCREENING	Worldlab-euromedlab Rome 2023	Rome	Congress	International	2023
Geni della salute ed esercizio fisico: un binomio per una sana longevità	XXXVII Congress National FMSI	Rome	Congress	National	2023

Cosa dice la genetica	Ictus giovanile: una condizione non cosi rara	Rome	Conference	National	2023
Genetic evaluation	The annual symposium of the regional reference centre for marfan syndrome and related disorders	Rome	Symposium	National	2023
La fabbrica degli organoidi nella medicina di precisione	Scillacuore 2023	Scilla	Conference	National	2023
"La medicina genomica: futuro strumento di prevenzione e cura	Cardio news 2023 sapere-prevenire-curare	Sorrento	Conference	National	2023
Il Metodo Scientifico Nella Ricerca Sperimentale	Meeting la scienza per la pace	Teramo	Conference	National	2023
Conoscere fa bene: il ruolo dell'health literacy nella promozione della salute	Festival dello sviluppo sostenibile - salone del libro	Torino		National	2023
Le prossime sfide e traguardi nella genomica	Promuovere l'innovazione nelle scienze della vita	Trieste	Conference	National	2023
Geni, Enzimi, e cromosomi...	50° anniversario della istituzione della facoltà scienze matematiche fisiche e naturali	Urbino	Lecture	National	2023
The bioeconomy and the construction of a "one health" system	26th ICABR conference agenda	Bologna	Congress	International	2022
Osserva, sperimenta ed impara: la scienza ai tempi del Covid	XXIX Course di aggiornamento in cardiologia	Bormio	Conference	National	2022
"Trappole molecolari": come impedire l'uscita di SarsCoV2 dalla cellula infettata	"L'ipotesi della regina rossa": le dinamiche co-evolutive tra virus e uomo. Profilassi, terapie e genere"	Ferrara	Conference	National	2022
Dalla genomica le chiavi di comprensione dei virus	La prevenzione vaccinale delle malattie infettive alla radice della sanità appulo-lucana	Matera	Conference	National	2022
Valutazione Rischio Genetico Riproduttivo	97° Congress SIGO	Milan	Congress	National	2022
Tetravalent Antibody Drugs for Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants	6th National Congress Of The Italian Society For Virology	Napoli	Congress	International	2022
Può la genetica predire il rischio di eventi gravi nell'atleta?	Cardiologia e sport quando l'attività sportiva è un alleato e quando è un nemico per il cuore	Rende (CS)	Conference	National	2022
Epigenetica e genere. Le radici dello sviluppo mentale	Medicina di genere e… come il genere influenza le tappe	Rimini	Conference	National	2022

	della nostra vita				
Toward Understanding The Genetic Basis Of Complex And Multifactorial Diseases	Advanced Research In Intestinal Inflammation And Cancer	Rome	Conference	International	2022
Precision Health: convergence of genomics and environment	XV Congress National SIMGEPED	Rome	Congress	National	2022
"Towards personalised medicine in COVID-19: Human genetic determinants and discovery of novel tetravalent antibody drugs neutralizing SARS-CoV-2 variants"	Public health conference at Temple Rome	Rome	Workshop	International	2022
"SARS-CoV2, un estraneo tra noi: scienza e fantascienza di una pandemia"	Dall' emergenza alla coesistenza con il Covid 19 criticità e spunti di riflessione sulla salute e la psiche	Rossano - Liceo Scientifico	Conference	National	2022
Osserva, Sperimenta ed impara: la Scienza ai tempi del COVID	Scilla cuore XXII edizione	Scilla (RC)	Conference	National	2022
Genomica nella medicina di precisione	Dai fattori di rischio allo sviluppo di scompenso cardiaco: strategie di prevenzione e trattamento	Sorrento	Conference	National	2022
Gli organoidi polmonari e le cellule staminali indotte	Pneumology Around The Clock: Lungs And Surroundings	Trani	Conference	National	2022
Genomics: instructions for a new fighting strategy to cardiovascular disease	XI Congress National SISMED	Venice	Congress	National	2022
Perspectives on COVID-19	Academia Europae	Online	Lecture	International	2022
Emergenza COVID 19. I vaccini cultura della prevenzione	Ordine National biologi	Online	Lecture	National	2022
La Genetica dell'Ospite nel COVID-19	Istituto Lombardo Accademia Delle Scienze	Milan	Lecture	National	2022
Le tecnologie dirompenti al tempo della pandemia: sostenibilità, investimenti e competenza	Università Degli Studi Di Rome Tor Vergata - Scuola Di Economia	Rome	Lecture	National	2022
COronaVIrusDisease(20)19 : What else in 2021?	Università Di Rome Tor Vergata - Scuola Di Economia	Rome	Lecture	National	2022
Le Malattie Rare	Approccio Multidisciplinare Nelle Malattie Genetiche E Rare	ANCONA	Congress	National	2021
Genetica e pandemia Covid19	Course IAWC	ASTI	School	National	2021
"Gene therapy, genetic enhancement: a dream or a	XXXVI Congress mondiale FIMS	ATHENS	Congress	International	2021

nightmare"					
Guarire dalle malattie Genetiche	Health Talks 2021: guarire! Le nuove frontiere della medicina	Casa dei Cavalieri di Rodi, Rome	Workshop	National	2021
Genetica e Genomica DEL COVID-19	L'impatto del covid-19 sul pianeta terra	Circolo Ufficiali dell'Aeronautica Militare	Conference	International	2021
B. Beutler: Innate Immunity and Genetics, XII and XIII Annual Weinman Symposium	University of Hawaii, Honolulu (USA)	Honolulu (USA)	Conference	International	2021
Host Genetics and Genomics in SARS-CoV-2 infection	Indian Society of Human Genetics	Kerala, India	Workshop	International	2021
Esiste una vulnerabilità maggiore degli uomini rispetto alle donne nel COVID	Medicina di genere	Lecco	Conference	National	2021
Il valore delle sperimentazioni cliniche	Sperimentazioni cliniche il processo di ricerca scientifica sull'uomo	Online	School	National	2021
Genetica e Genomica SARS-CoV-2	Festival della Scienza	Padua	Festival	National	2021
COVID-19 and genetic susceptibility	Joint in Rheumathology 2021	Rome	Conference	National	2021
Il virus, l'ospite	Congress Società Italiana Di Cardiologia SIC	Rome	Congress	National	2021
Genetica e genomica dell'ospite nel covid 19	Scilla cuore	Scilla	Conference	National	2021
Suscettibilità Genetica al COVID-19	X Congress National SISMED	Sorrento	Congress	National	2021
Genetics and Genomics underlying COVID-19	Burlo PhD week	Trieste	School	National	2021
Ruolo della genetica dell'ospite e SARS-COV2	Geni di suscettibilità nelle malattie infettive	Venice	Conference	National	2021
La genetica ci aiuta ad essere precisi	122° Congress National SIM	Virtuale	Congress	National	2021
COVID-19 Genetics and Genomics	Sobratafe global advanced wound care meeting 2021	Webinar	Congress	International	2021

RECENT PAPERS (2024-2025)

1. Pecorelli S, Lucchini R, Lambertini L, Novelli G. Fathers matter too: sperm-borne epigenetic messages link paternal exposures to next-generation health. Nat. Rev Urol. 2026 Feb 4. doi: 10.1038/s41585-026-01128-9. Epub ahead of print. PMID: 41639335.
2. Colangeli L, Teofani A, Desideri A, Biocca S, Pacifico T, Parrotta ME, Fertitta V, Fortini P, Ceccarini G, Magno S, Pelosini C, Santini F, Novelli G, Sbraccia P, Guglielmi V. Gut Microbiota in Lipodystrophies and Obesity: A Common Signature? Microorganisms. 2026 Jan 7;14(1):132. doi: 10.3390/microorganisms14010132. PMID: 41597651; PMCID: PMC12843611.
3. D'Apolito M, D'Apice MR, Santoro F, Patrizio MP, Ranaldi A, Botta A, D'Andrea G, Santacroce R, Novelli G, Margaglione M. Unmasking Brugada ECG Pattern in Myotonic Dystrophy Type 2 With an ANK2

Variant. Pacing Clin Electrophysiol. 2026 Feb 24. doi: 10.1111/pace.70191. Epub ahead of print. PMID: 41733445.
4. Hu L, van der Sluis RM, Castelino KB, et al., Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2. Nat Commun. 2025 Nov 27;16(1):10618. doi: 10.1038/s41467-025-65308-8. PMID: 41309545; PMCID: PMC12660716.
5. De Benedittis G, Latini A, Morgante C, Bonini C, Cela E, Kroegler B, Luciano A, Chiocchi M, Cavalli F, Ora J, Rogliani P, Novelli G, Ciccacci C, Chimenti MS, Conigliaro P, Borgiani P. Alteration of telomere length and mtDNA copy number in interstitial lung disease associated with rheumatoid arthritis. Autoimmunity. 2025 Dec;58(1):2473741. doi: 10.1080/08916934.2025.2473741. Epub 2025 Mar 4. PMID: 40035723.
6. Latini A, Spitalieri P, Centofanti F, Rizzacasa B, Amatore D, Grilli G, De Santis R, Vaccaro L, Colona VL, Puleri G, Nardone AM, Biancolella M, Campione E, Sarmati L, Rogliani P, Cacchiarelli D, Novelli A, Sangiuolo F, Lista F, Novelli G. Modelling severe COVID-19 in TLR3-mutated hiPSCs-derived lung organoids. Cell Death Discov. 2025 Dec 26;12(1):74. doi: 10.1038/s41420-025-02936-5. PMID: 41453867; PMCID: PMC12858893.
7. Calò L, Crescenzi C, Di Marco A, et al., Novelli G. The Diagnostic and Prognostic Value of the 12-Lead ECG in Arrhythmogenic Left Ventricular Cardiomyopathy. JACC Adv. 2025 Jun;4(6 Pt 1):101766. doi: 10.1016/j.jacadv.2025.101766. Epub 2025 May 12. PMID: 40359643; PMCID: PMC12141911.
8. Minotti C, Terreri S, Del Fattore A, et al., Further Exploring the TRRAP Genotype-Phenotype Correlations: Report of Three New Patients With A Focus on Skeletal Anomalies. Clin Genet. 2026 Jan;109(1):181-187. doi: 10.1111/cge.70013. Epub 2025 Jun 29. PMID: 40583039; PMCID: PMC12674977.
9. Marchionni E, Mannucci L, Di Tommaso S, Nardone AM, Albanese M, Novelli A, Sangiuolo FC, Triggianese P, Novelli G. Unexpected genomic architecture in a sporadic case of C1-INH Hereditary Angioedema: the hidden heritability. Orphanet J Rare Dis. 2025 Nov 5;20(1):562. doi: 10.1186/s13023-025-04092-6. PMID: 41194199; PMCID: PMC12587510.
10. Greco G, Motta C, Marchionni E, D'Apice MR, Carrese C, Novelli G, Martorana A, Bonomi CG. An Out-of-Place Etiology: Recognizing FMR1 Premutation in the Memory Clinic. Ann Clin Transl Neurol. 2026 Mar;13(3):607-611. doi: 10.1002/acn3.70286. Epub 2025 Dec 15. PMID: 41398615; PMCID: PMC12968457.
11. Murdocca M, Pepe G, Maccaroni S, Spitalieri P, Helmer-Citterich M, Novelli G, Sangiuolo F. Transcriptome profiling of human dermal MDPL fibroblasts reveals a characteristic molecular signature providing insights into pathogenic mechanisms. J Mol Med (Berl). 2025 Nov;103(11-12):1503-1513. doi: 10.1007/s00109-025-02597-y. Epub 2025 Oct 13. PMID: 41083899; PMCID: PMC12675696.
12. Murdocca M, Romeo I, Maccaroni S, Curcio A, Pepe G, Helmer-Citterich M, Alcaro S, Novelli G, Sangiuolo F. Structural and functional impact of the POLD1 Ser605del variant in MDPL syndrome: insights from protein-protein interactions. Hum Genomics. 2025 Nov 12;19(1):131. doi: 10.1186/s40246-025-00848-0. PMID: 41219970; PMCID: PMC12606881.
13. Marchionni E, Mannucci L, Di Tommaso S, Nardone AM, Albanese M, Novelli A, Sangiuolo FC, Triggianese P, Novelli G. Unexpected genomic architecture in a sporadic case of C1-INH Hereditary Angioedema: the hidden heritability. Orphanet J Rare Dis. 2025 Nov 5;20(1):562. doi: 10.1186/s13023-025-04092-6. PMID: 41194199; PMCID: PMC12587510.
14. Cusumano A, Lombardo M, Falsini B, D'Ambrosio M, Sebastiani J, Marchionni E, D'Apice MR, Rizzacasa B, Martelli F, Novelli G. Longitudinal Multimodal Assessment of Structure and Function in INPP5E-Related Retinopathy. Genes (Basel). 2025 Nov 26;16(12):1407. doi: 10.3390/genes16121407. PMID: 41465079; PMCID: PMC12732851.
15. Greco G, Motta C, Marchionni E, D'Apice MR, Carrese C, Novelli G, Martorana A, Bonomi CG. An Out-of-Place Etiology: Recognizing FMR1 Premutation in the Memory Clinic. Ann Clin Transl Neurol. 2025 Dec 15. doi: 10.1002/acn3.70286. Epub ahead of print. PMID: 41398615.
16. Latini A, Spitalieri P, Centofanti F, Rizzacasa B, Amatore D, Grilli G, De Santis R, Vaccaro L, Colona VL, Puleri G, Nardone AM, Biancolella M, Campione E, Sarmati L, Rogliani P, Cacchiarelli D, Novelli A, Sangiuolo F, Lista F, Novelli G. Modelling severe COVID-19 in TLR3-mutated hiPSCs-derived lung organoids. Cell Death Discov. 2025 Dec 26. doi: 10.1038/s41420-025-02936-5. Epub ahead of print. PMID: 41453867.
17. Hu L, van der Sluis RM, Castelino KB, Zhang BC, Ronit A, Zillinger T, Werner M, Jørgensen SE, Hansen AL, Pedersen A, Narita R, Reinert LS, Bundgaard B; COVID Human Genetic Effort; Holm CK, Cobat A, Casanova JL, Reggiori F, Mari M, Paludan SR, Mogensen TH. Deleterious variants in the autophagy-

related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2. Nat Commun. 2025 Nov 27;16(1):10618. doi: 10.1038/s41467-025-65308-8. PMID: 41309545; PMCID: PMC12660716.
18. De Benedittis G, Latini A, Morgante C, Bonini C, Cela E, Kroegler B, Luciano A, Chiocchi M, Cavalli F, Ora J, Rogliani P, Novelli G, Ciccacci C, Chimenti MS, Conigliaro P, Borgiani P. Alteration of telomere length and mtDNA copy number in interstitial lung disease associated with rheumatoid arthritis. Autoimmunity. 2025 Dec;58(1):2473741. doi: 10.1080/08916934.2025.2473741. Epub 2025 Mar 4. PMID: 40035723.
19. Graziani L, Carriero ML, Ferradini V, Conte C, Bengala M, Sangiuolo FC, Novelli G. WDFY3 Haploinsufficiency Is Associated With Autosomal Dominant Neurodevelopmental Disorders and Macrocephaly. Clin Genet. 2025 Mar;107(3):369-370. doi: 10.1111/cge.14665. Epub 2024 Nov 29. PMID: 39614649.
20. Ceccarini G, et al., ECLip Registry Consortium. Epidemiological and Clinical Data from the European lipodystrophy (ECLip)
21. registry. Eur J Endocrinol. 2025 Oct 28:lvaf214. doi: 10.1093/ejendo/lvaf214. Epub ahead of print. PMID: 41152002
22. Calò L, Crescenzi C, Di Marco A, Fanisio F, Romeo F, Gargaro A, Martino A, Cappelletto C, Merlo M, Targetti M, Toso E, Toto F, Musumeci MB, Tini G, Ciabatti M, Stefanini M, Canestrelli S, Fedele E, Lanzillo C, Fusco A, Sangiuolo FC, Radesich C, Perotto M, Pieroni M, Mango R, Gasperetti A, Autore C, Casella M, Dello Russo A, Stolfo D, Laredo M, Gandjbakhch E, Graziosi M, Biagini E, Catalano C, Barile L, Drago F, Cicenia M, Baban A, Pelargonio G, Narducci ML, Re F, Peretto G, Paiotti E, Díez-López C, Olivotto I, Gaita F, Sinagra G, Novelli G. The Diagnostic and Prognostic Value of the 12-Lead ECG in Arrhythmogenic Left Ventricular Cardiomyopathy. JACC Adv. 2025 Jun;4(6 Pt 1):101766. doi: 10.1016/j.jacadv.2025.101766. Epub 2025 May 12. PMID: 40359643; PMCID: PMC12141911.
23. Minotti C, Graziani L, Micalizzi A, Dentici ML, Capolino R, Sinibaldi L, Lanari V, Dallapiccola B, Novelli G, Novelli A, Digilio MC. Clinical Variability of Shashi-Pena Syndrome: A Novel ASXL2 Variant Associated with Overgrowth and Minor Neurodevelopmental Features. Mol Syndromol. 2025 May;16(3):252-258. doi: 10.1159/000541070. Epub 2024 Oct 10. PMID: 40475172; PMCID: PMC12136562.
24. Minotti C, Terreri S, Del Fattore A, Lepri FR, Ruta R, Iascone M, Pezzoli L, Dentici ML, Novelli A, Armando M, Longo D, Novelli G, Barbuti D, Bartuli A, Cavallari U, Graziani L, Digilio MC, Sinibaldi L. Further Exploring the TRRAP Genotype-Phenotype Correlations: Report of Three New Patients With A Focus on Skeletal Anomalies. Clin Genet. 2025 Jun 29. doi: 10.1111/cge.70013. Epub ahead of print. PMID: 40583039.
25. Caputo V, Visconti VV, Marchionni E, Ferradini V, Balsano C, De Vico P, Calò L, Mango R, Novelli G, Sangiuolo F. The Diagnostic Value of Copy Number Variants in Genetic Cardiomyopathies and Channelopathies. J Cardiovasc Dev Dis. 2025 Jul 4;12(7):258. doi: 10.3390/jcdd12070258. PMID: 40710783; PMCID: PMC12295415.
26. Marchionni E, Lomuscio S, Latini A, Murdocca M, Romeo F, Crescenzi C, Calò L,Novelli G, Mango R, Sangiuolo F. Arrhythmogenic CardiomyopathyPKP2-Related: Clinical and Functional Characterization of a PathogenicVariant Detected in Two Italian Families. Genes (Basel). 2025 Mar 31;16(4):419.doi: 10.3390/genes16040419. PMID: 40282378; PMCID: PMC12027432.
27. Belardi R, Pacifici F, Baldetti M, Velocci S, Minieri M, Pieri M, Campione E,Della-Morte D, Tisone G, Anselmo A, Novelli G, Bernardini S, Terrinoni A. Trendsin Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing aCorrect Immunosuppressive Therapy for Kidney Transplant: An Up-to-DateHistorical Overview. Int J Mol Sci. 2025 Feb 24;26(5):1960. doi:10.3390/ijms26051960. PMID: 40076585; PMCID: PMC11900248.
28. De Benedittis G, Latini A, Morgante C, Bonini C, Cela E, Kroegler B, LucianoA, Chiocchi M, Cavalli F, Ora J, Rogliani P, Novelli G, Ciccacci C, Chimenti MS,Conigliaro P, Borgiani P. Alteration of telomere length and mtDNA copy number ininterstitial lung disease associated with rheumatoid arthritis. Autoimmunity.2025 Dec;58(1):2473741. doi: 10.1080/08916934.2025.2473741. Epub 2025 Mar 4.PMID: 40035723.
29. Infante M, Silvestri F, Padilla N, Pacifici F, Pastore D, Pinheiro MM, CaprioM, Tesauro M, Fabbri A, Novelli G, Alejandro R, De Lorenzo A, Ricordi C, Della-Morte D. Unveiling the Therapeutic Potential of the Second-Generation IncretinAnalogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent AutoimmuneDiabetes in Adults. J Clin Med. 2025 Feb 15;14(4):1303. doi:10.3390/jcm14041303. PMID: 40004833; PMCID: PMC11856673.
30. Latini A, De Benedittis G, Morgante C, Gasperini B, D'Ippolito I, Lauro D,Novelli G, Ciccacci C, Spallone V, Borgiani P. Correlation between Sirtuin 1downregulation and reduced vitamin D receptor expression

in patients withdiabetic neuropathy. Acta Diabetol. 2025 Feb 20. doi:10.1007/s00592-025-02463-w. Epub ahead of print. PMID: 39976627.
31. Morgante C, Latini A, De Benedittis G, Novelli G, Spallone V, Ciccacci C,Borgiani P. A genetic variant in the potassium channel (KCNJ11) gene isassociated with diabetic retinopathy in type 2 diabetes patients. Gene. 2025 Apr15;945:149289. doi: 10.1016/j.gene.2025.149289. Epub 2025 Feb 5. PMID: 39921046.
32. Malaspina P, Jodice C, Ciminelli BM, Biancolella M, Colona VL, Latini A,Leonardis F, Rogliani P, Novelli A, Novelli G, Novelletto A. Genetic diversityof the immunoglobulin heavy chain locus in cohorts of patients affected withSARS-CoV-2. Hum Genomics. 2025 Jan 30;19(1):7. doi: 10.1186/s40246-025-00719-8.PMID: 39885568; PMCID: PMC11780896.
33. Lomuscio S, Cocciadiferro D, Petrizzelli F, Liorni N, Mazza T, Allegorico A,Ullmann N, Novelli G, Cutrera R, Novelli A. Two Novel Biallelic Variants in theFARSA Gene: The First Italian Case and a Literature Review. Genes(Basel). 2024 Dec 5;15(12):1573. doi: 10.3390/genes15121573. PMID: 39766840;PMCID: PMC11675362.
34. Al Qureshah F, Le Pen J, de Weerd NA, Moncada-Velez M, Materna M, Lin DC,Milisavljevic B, Vianna F, Bizien L, Lorenzo L, Lecuit M, Pommier JD, Keles S,Ozcelik T, Pedraza-Sanchez S, de Prost N, El Zein L, Hammoud H, Ng LFP, HalwaniR, Saheb Sharif-Askari N, Lau YL, Tam AR, Singh N, Bhattad S, Berkun Y,Chantratita W, Aguilar-López R, Shahrooei M; COVID-19 HGE Consortium; SEAeConsortium; Abel L, Bastard P, Jouanguy E, Béziat V, Zhang P, Rice CM, Cobat A,Zhang SY, Hertzog PJ, Casanova JL, Zhang Q. A common form of dominant humanIFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity. J ExpMed. 2025 Feb 3;222(2):e20241413. doi: 10.1084/jem.20241413. Epub 2024 Dec 16.PMID: 39680367; PMCID: PMC11648951.
35. Ranucci G, Page C, Marchionni E, Minotti C, Silvestrini G, Gastaldi S,Pacitto G, Cicconi L, Biagi A, Ferradini V, Attardi E, Novelli G, Sangiuolo F,Voso MT, Gurnari C. Donor selection for allogeneic hematopoietic cell transplantin a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germlinevariant. Ann Hematol. 2024 Dec;103(12):5999-6002. doi:10.1007/s00277-024-06140-w. Epub 2024 Dec 14. PMID: 39672944.
36. Stellacci E, Martinelli S, Carbone P, Demuru E, Genuardi M, Ghiorzo P,Novelli G, Di Pucchio A, Regini FM, Guerrera D, Vittozzi A, Barbina D, VenanziS, van den Bulcke M, Boccia S, Mazzaccara A, De Nicolo A, De Angelis R. Bridgingthe educational gaps of health professionals in oncogenomics: results from apilot e-learning course. Front Med (Lausanne). 2024 Nov 21; 1422163. doi:10.3389/fmed.2024.1422163. PMID: 39640978; PMCID: PMC11617149.
37. Graziani L, Carriero ML, Ferradini V, Conte C, Bengala M, Sangiuolo FC,Novelli G. WDFY3 Haploinsufficiency Is Associated With Autosomal DominantNeurodevelopmental Disorders and Macrocephaly. Clin Genet. 2025Mar;107(3):369-370. doi: 10.1111/cge.14665. Epub 2024 Nov 29. PMID: 39614649.
38. Bellos E, Santillo D, Vantourout P, Jackson HR, Duret A, Hearn H,Seeleuthner Y, Talouarn E, Hodeib S, Patel H, Powell O, Yeoh S, Mustafa S,Habgood-Coote D, Nichols S, Estramiana Elorrieta L, D'Souza G, Wright VJ,Estrada-Rivadeneyra D, Tremoulet AH, Dummer KB, Netea SA, Condino-Neto A, LauYL, Núñez Cuadros E, Toubiana J, Holanda Pena M, Rieux-Laucat F, Luyt CE,Haerynck F, Mège JL, Chakravorty S, Haddad E, Morin MP, Metin Akcan Ö, Keles S,Emiroglu M, Alkan G, Tüter Öz SK, Elmas Bozdemir S, Morelle G, Volokha A,Kendir-Demirkol Y, Sözeri B, Coskuner T, Yahsi A, Gulhan B, Kanik-Yuksek S,Bayhan GI, Ozkaya-Parlakay A, Yesilbas O, Hatipoglu N, Ozcelik T, Belot A,Chopin E, Barlogis V, Sevketoglu E, Menentoglu E, Gayretli Aydin ZG, BloomfieldM, AlKhater SA, Cyrus C, Stepanovskiy Y, Bondarenko A, Öz FN, Polat M, FremuthJ, Lebl J, Geraldo A, Jouanguy E; COVID-19 Human Genetic Effort; DIAMONDS;EUCLIDS; Carter MJ, Wellman P, Peters M, Pérez de Diego R, Edwards LA, Chiu C,Noursadeghi M, Bolze A, Shimizu C, Kaforou M, Hamilton MS, Herberg JA, SchmittEG, Rodriguez-Palmero A, Pujol A, Kim J, Cobat A, Abel L, Zhang SY, Casanova JL,Kuijpers TW, Burns JC, Levin M, Hayday AC, Sancho-Shimizu V. Heterozygous BTNL8variants in individuals with multisystem inflammatory syndrome in children(MIS-C). J Exp Med. 2024 Dec 2;221(12):e20240699. doi: 10.1084/jem.20240699.Epub 2024 Nov 22. PMID: 39576310; PMCID: PMC11586762.
39. Sax SL, Centomo ML, Centofanti F, Rizzacasa B, Cox S, Cox C, Latini A,D'Apice MR, Mannucci L, Novelli G, Pandolfi PP. The Senolytic Effect ofIndole-3-Carbinol (I3C) on Mouse Embryonic (MEF) and Human Fibroblast CellLines. Int J Mol Sci. 2024 Oct 30;25(21):11652. doi: 10.3390/ijms252111652.PMID: 39519210; PMCID: PMC11546363.
40. Perricone C, Bruno L, Cafaro G, Latini A, Ceccarelli F, Borgiani P, CiccacciC, Bogdanos D, Novelli G, Gerli R, Bartoloni E. Sjogren's syndrome: Everythingyou always wanted to know about genetic and epigenetic factors. Autoimmun Rev.2024 Dec;23(12):103673. doi: 10.1016/j.autrev.2024.103673. Epub 2024 Oct

28.PMID: 39490751.
41. Rizzacasa B, Nicolì V, Tancredi C, Conte C, Salehi LB, Carriero ML, Longo G,Cirigliano V, Lopez LI, Palao B, Portarena I, Buonomo OC, Novelli G, BiancolellaM. Implementing the Risk Stratification and Clinical Management of Breast CancerFamilies Using Polygenic Risk Score Evaluation: A Pilot Study. J Pers Med. 2024Sep 27;14(10):1034. doi: 10.3390/jpm14101034. PMID: 39452541; PMCID:PMC11508219.
42. Murdocca M, Andrade Santos-Filho O, De Masi C, Dos Santos Rodrigues E,Campos de Souza CV, De Santis R, Amatore D, Latini A, Schipani R, di RienzoBusinco L, Brandimarte B, Grilli G, Huang TL, Mayence AS, Lista F, Duranti A,Sangiuolo F, Vanden Eynde JJ, Novelli G. Characterization of the symmetricalbenzimidazole twin drug TL1228: the role as viral entry inhibitor for fightingCOVID-19. Biol Direct. 2024 Oct 16;19(1):93. doi: 10.1186/s13062-024-00523-9.PMID: 39415197; PMCID: PMC11481581.
43. Novelli G, Calcaterra G, Casciani F, Pecorelli S, Mehta JL. 'Exerkines': AComprehensive Term for the Factors Produced in Response to Exercise.Biomedicines. 2024 Sep 1;12(9):1975. doi: 10.3390/biomedicines12091975. PMID:39335489; PMCID: PMC11429193.
44. De Benedittis G, Latini A, Morgante C, Perricone C, Ceccarelli F, Novelli G,Novelli L, Ciccacci C, Borgiani P. The dysregulation of mitochondrialhomeostasis-related genes could be involved in the decrease of mtDNA copy numberin systemic lupus erythematosus patients. Immunol Res. 2024 Dec;72(6):1384-1392.doi: 10.1007/s12026-024-09535-z. Epub 2024 Sep 4. PMID: 39230799; PMCID:PMC11618193.
45. Graziani L, Carriero ML, Pozzi F, Minotti C, Andreadi A, Bellia A, Ruta R,Bengala M, Novelli A, Lauro D, Novelli G. Genetic Variability ofSOX10-Related Disorders within an Italian Family: Straddling the Line between Kallmann and Waardenburg Syndrome. Mol Syndromol. 2024Aug;15(4):339-346. doi: 10.1159/000536574. Epub 2024 Mar 22. PMID: 39119450;PMCID: PMC11305686.
46. Murdocca M, Romeo I, Citro G, Latini A, Centofanti F, Bugatti A, Caccuri F,Caruso A, Ortuso F, Alcaro S, Sangiuolo F, Novelli G. A Dynamic and EffectivePeptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants ofConcern. Pharmaceuticals (Basel). 2024 Jul 4;17(7):891. doi: 10.3390/ph17070891.PMID: 39065742; PMCID: PMC11279616.
47. Jodice C, Malaspina P, Ciminelli BM, Martinez-Labarga C, Biancolella M,Novelli G, Novelletto A. Variation of the 3'RR1 HS1.2 Enhancer and Its GenomicContext. Genes (Basel). 2024 Jun 29;15(7):856. doi: 10.3390/genes15070856. PMID:39062635; PMCID: PMC11275349.
48. Meazzini MC, Moretti M, Canzi G, Sozzi D, Novelli G, Mazzoleni F. MaxillaryHypoplasia and Non-Invasive Ventilation: Literature Review and Proposed NewTreatment Protocol. Children (Basel). 2024 Jun 13;11(6):720. doi:10.3390/children11060720. PMID: 38929299; PMCID: PMC11201370.
49. 2Graziani L, Minotti C, Carriero ML, Bengala M, Lai S, Terracciano A, NovelliA, Novelli G. A Novel COL4A5 Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease. Genes (Basel). 2024 May 8;15(5):597. doi: 10.3390/genes15050597. PMID:38790225; PMCID: PMC11121527.
50. Vancheri C, Quatrana A, Morini E, Mariotti C, Mongelli A, Fichera M, RufiniA, Condò I, Testi R, Novelli G, Malisan F, Amati F. An RNA-seq study inFriedreich ataxia patients identified hsa-miR-148a-3p as a putative prognosticbiomarker of the disease. Hum Genomics. 2024 May 22;18(1):50. doi:10.1186/s40246-024-00602-y. PMID: 38778374; PMCID: PMC11110315.
51. De Benedittis G, D'Antonio A, Latini A, Morgante C, Conigliaro P,Triggianese P, Bergamini A, Novelli G, Ciccacci C, Chimenti MS, Borgiani P.Study of lncRNAs expression profile in the response to biological drugs inPsoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapyefficacy. Int Immunopharmacol. 2024 Jun 15;134:112239. doi:10.1016/j.intimp.2024.112239. Epub 2024 May 17. PMID: 38761785.
52. Graziani L, Nuovo S, Pisaneschi E, Carriero ML, Baghernajad Salehi L,Nardone AM, Manganaro L, Novelli A, D'Apice MR, Mappa I, Novelli G. Prenatal identification of a pathogenic maternal FGFR1 variant in two consecutive pregnancies with fetal forebrain malformations. J Matern Fetal Neonatal Med.2024 Dec;37(1):2344718. doi: 10.1080/14767058.2024.2344718. Epub 2024 Apr 28.PMID: 38679587.
53. Marchal A, Cirulli ET, Neveux I, Bellos E, Thwaites RS, Schiabor Barrett KM,Zhang Y, Nemes-Bokun I, Kalinova M, Catchpole A, Tangye SG, Spaan AN, Lack JB,Ghosn J, Burdet C, Gorochov G, Tubach F, Hausfater P; COVID Human GeneticEffort; COVIDeF Study Group; French COVID Cohort Study Group; CoV-ContactCohort; COVID-STORM Clinicians; COVID Clinicians; Orchestra Working Group;Amsterdam UMC COVID-19 Biobank; NIAID-USUHS COVID Study Group; Dalgard CL, ZhangSY, Zhang Q, Chiu C, Fellay J, Grzymski JJ, Sancho-Shimizu V, Abel L, CasanovaJL, Cobat A, Bolze A. Lack of association between classical HLA genes andasymptomatic SARS-CoV-2 infection. HGG Adv. 2024 Jul

18;5(3):100300. doi:10.1016/j.xhgg.2024.100300. Epub 2024 Apr 26. PMID: 38678364; PMCID:PMC11215417.

54. Latini A, Borgiani P, De Benedittis G, Ciccacci C, Novelli L, Pepe G,Helmer-Citterich M, Baldini I, Perricone C, Ceccarelli F, Conti F, IannicielloG, Caceres J, Ottalevi R, Capulli M, Novelli G. Large-scale DNA sequencingidentifies rare variants associated with Systemic Lupus Erythematosussusceptibility in known risk genes. Gene. 2024 May 20;907:148279. doi:10.1016/j.gene.2024.148279. Epub 2024 Feb 13. PMID: 38360126.

Pursuant to EU Regulation 2016/679 of 27 April 2016 on the protection of individuals with regard to the processing of personal data and Legislative Decree 196/2003, the subscriber declares to have read the complete information attached to this document.

F.to Giuseppe Novelli

I, the undersigned Giuseppe Novelli, born in Rossano (CS), on 27/02/1959 and resident in Rome, aware of the criminal consequences deriving from false and false declarations, as required by art. 76 of the D.P.R. n. 445/2000, I certify that everything reported in the curriculum corresponds to truth.

F.to Giuseppe Novelli

Riproduzione in formato privacy del documento originale depositato agli atti.